Literature DB >> 3038642

Altered action of glucagon on human liver in type 2 (non-insulin-dependent) diabetes mellitus.

P Arner, K Einarsson, S Ewerth, J N Livingston.   

Abstract

Glucagon may play a role in the metabolic derangements of overt Type 2 (non-insulin-dependent) diabetes mellitus. We therefore have evaluated the early steps in glucagon action by investigating the hormone-sensitive adenylyl cyclase system in liver membranes from seven Type 2 diabetic patients with fasting hyperglycaemia and two-fold elevations in plasma glucagon. The comparison was made with seven control subjects matched for age, sex and body weight. Glucagon receptor binding was almost identical in the two groups. There were, however, marked alterations in the adenylyl cyclase activity in membranes from the diabetic patients. This activity was reduced by 35-50% when compared to control activity. Basal cyclase activity, as well as the activity after stimulation with glucagon or with agents (i.e., sodium fluoride and forskolin) that act beyond the glucagon receptor, was significantly decreased (p less than 0.05, p less than 0.001 respectively). In conclusion, uncontrolled Type 2 diabetes in associated with an over-all loss of responsiveness of the hormone-sensitive adenylyl cyclase in human liver, which apparently results from post-receptor alterations. This change may provide a mechanism for reducing the effect of hyperglycagonaemia in Type 2 diabetes mellitus.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3038642     DOI: 10.1007/BF00299025

Source DB:  PubMed          Journal:  Diabetologia        ISSN: 0012-186X            Impact factor:   10.122


  12 in total

1.  Glucagon and the A cell: physiology and pathophysiology (second of two parts).

Authors:  R H Unger; L Orci
Journal:  N Engl J Med       Date:  1981-06-25       Impact factor: 91.245

2.  A regulatory component of adenylate cyclase from human erythrocyte membranes.

Authors:  H R Kaslow; G L Johnson; V M Brothers; H R Bourne
Journal:  J Biol Chem       Date:  1980-04-25       Impact factor: 5.157

3.  Glucagon receptor of human liver. Studies of its molecular weight and binding properties, and its ability to activate hepatic adenylyl cyclase of non-obese and obese subjects.

Authors:  J N Livingston; K Einarsson; L Backman; S Ewerth; P Arner
Journal:  J Clin Invest       Date:  1985-02       Impact factor: 14.808

4.  Glucagon-stimulable adenylyl cyclase in rat liver. The impact of streptozotocin-induced diabetes mellitus.

Authors:  R R Dighe; F J Rojas; L Birnbaumer; A J Garber
Journal:  J Clin Invest       Date:  1984-04       Impact factor: 14.808

Review 5.  Glucagon physiology and pathophysiology in the light of new advances.

Authors:  R H Unger
Journal:  Diabetologia       Date:  1985-08       Impact factor: 10.122

6.  Studies of the human liver insulin receptor in noninsulin-dependent diabetes mellitus.

Authors:  P Arner; K Einarsson; S Ewerth; J Livingston
Journal:  J Clin Invest       Date:  1986-05       Impact factor: 14.808

7.  Forskolin regulation of liver membrane adenylyl cyclase.

Authors:  L Birnbaumer; D Stengel; M Desmier; J Hanoune
Journal:  Eur J Biochem       Date:  1983-10-17

8.  Absence of the inhibitory effect of guanine nucleotides on adenylate cyclase activity in white adipocyte membranes of the ob/ob mouse. Effect of the ob gene.

Authors:  N Bégin-Heick
Journal:  J Biol Chem       Date:  1985-05-25       Impact factor: 5.157

9.  The effect of chronic sulfonylurea therapy on hepatic glucose production in non-insulin-dependent diabetes.

Authors:  J D Best; R G Judzewitsch; M A Pfeifer; J C Beard; J B Halter; D Porte
Journal:  Diabetes       Date:  1982-04       Impact factor: 9.461

10.  Studies of liver insulin receptors in non-obese and obese human subjects.

Authors:  P Arner; K Einarsson; L Backman; K Nilsell; K M Lerea; J N Livingston
Journal:  J Clin Invest       Date:  1983-11       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.